GPCPD1 and renal carcinoma: Huang et al. found that the expression of cicrSNX6 (hsa_circ_0031607) was up-regulated in sunitinib-resistant renal cancer cell lines by RNA-seq, and verified that circSNX6 can sponge miR-1184 and inhibit Glycerophosphocholine Phosphodiesterase 1 (GPCPD1), and then increased the content of Lysophosphatidic Acid (LPA) in cells, which eventually led to the enhancement of drug resistance of renal cancer cells to sunitinib [51].